EMA Validates Marketing Authorization Application for Henlius’ HANSIZHUANG (Serplulimab)
(Adnkronos) – SHANGHAI, March 23, 2023 /PRNewswire/ — Shanghai Henlius Biotech, Inc. (2696.HK) announced that the European Medicines Agency (EMA) has validated the application for its self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab), in
